Brincidofovir: A Novel Agent for the Treatment of Smallpox

Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation

(2021) Kirk Chan-Tack et al.   ANTIVIRAL RESEARCH

Drug development against smallpox: present and future.

(2020) Déborah Delaune et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Reevaluating the Risk of Smallpox Reemergence

(2020) C Raina MacIntyre   MILITARY MEDICINE

Smallpox

(2020) Joel G Breman   JOURNAL OF INFECTIOUS DISEASES

Oral Tecovirimat for the Treatment of Smallpox

(2018) Douglas W. Grosenbach et al.   NEW ENGLAND JOURNAL OF MEDICINE

Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments

(2018) Ryan S. Noyce et al.   PLoS One

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation

(2018) Francisco M. Marty et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak

(2017) Scott Foster et al.   Viruses-Basel

Switch From Existing Antivirals to Brincidofovir Leads to Improving Renal Function.

(2017) M. Morrison et al.   TRANSPLANTATION

Case report

(2016) Emmanuel Faure et al.   MEDICINE

Brincidofovir Is Not A Substrate For The Human Organic Anion Transporter 1 (Oat1)

(2016) Timothy K. Tippin et al.   THERAPEUTIC DRUG MONITORING

Postchallenge Administration of Brincidofovir Protects Healthy and Immune-Deficient Mice Reconstituted with Limited Numbers of T Cells from Lethal Challenge with IHD-J-Luc Vaccinia Virus

(2015) Marina Zaitseva et al.   JOURNAL OF VIROLOGY

In VitroEfficacy of Brincidofovir against Variola Virus

(2014) Victoria A. Olson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation

(2013) Francisco M. Marty et al.   NEW ENGLAND JOURNAL OF MEDICINE

First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses

(2012) Wendy Painter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans

(2011) Amanda D. Rice et al.   Viruses-Basel

Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans

(2011) Amanda D. Rice et al.   Viruses-Basel

Development of CMX001 for the Treatment of Poxvirus Infections

(2010) Randall Lanier et al.   Viruses-Basel

Cidofovir Activity against Poxvirus Infections

(2010) Graciela Andrei et al.   Viruses-Basel

Development of ST-246® for Treatment of Poxvirus Infections

(2010) Robert Jordan et al.   Viruses-Basel

Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model

(2007) Scott Parker et al.   ANTIVIRAL RESEARCH